26 Sep 2008 12:42
| For immediate release | 26 September 2008 |
ABCAM PLC
("Abcam" or "the Company")
Shareholding
Cambridge UK, 26 September 2008: Abcam plc announces that in accordance with the FSA's Disclosure and Transparency Rules, the Company was notified on 25 September 2008 that, as at 25 September 2008, NW Brown Nominees Limited had an indirect interest in voting rights over 3,960,500 ordinary shares of 1p each in the Company amounting to approximately 11.28% of the issued share capital of the Company.
For further information please contact:
| Abcam | + 44 (0) 1223 696000 |
| Jonathan Milner, Chief Executive Officer | |
| Jeff Iliffe, Chief Financial Officer www.abcam.com | |
| Numis Securities | + 44 (0) 20 7776 1500 |
| Michael Meade / Nick Westlake (Nominated Adviser) James Black (Corporate Broking) | |
| Buchanan Communications | + 44 (0) 20 7466 5000 |
| Mark Court / Mary-Jane Johnson |
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, UK, with a US office located in Cambridge, Massachusetts and a Japanese office in Tokyo. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third party produced antibodies to academic and commercial users throughout the world with product information provided and ordering available through the Company's website, www.abcam.com. The antibodies are sold under the Abcam brand name. The Company's vision is to build the largest online antibody resource in the world while also ensuring that the antibodies are of high quality and commercially viable. Abcam now has an online catalogue of over 45,000 products, most of which are antibodies, from over 200 suppliers supported by up-to-date and detailed technical data sheets, which are created by the Company. The Company currently employs approximately 184 staff in its three operating companies.